<DOC>
	<DOCNO>NCT01868581</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial test bioequivalence two explorative formulation insulin degludec ( insulin 454 ) two explorative insulin degludec/insulin aspart ( IDegAsp - formerly SIAC ) formulation , without buffer , healthy male subject . The investigated formulation explorative , similar propose commercial formulation .</brief_summary>
	<brief_title>Bioequivalence Between Two Explorative Insulin Degludec Formulations Between Two Explorative IDegAsp Formulations Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trial related activity procedure would perform normal management subject Considered generally healthy upon completion medical history physical examination judge Investigator Body mass index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) Fasting plasma glucose equal 6 mmol/L Sexually active nonsterilised participant must inform partner must use safe method contraception sexual intercourse ( risk pregnancy must lower 1 % ) , e.g . implant , injection , combine oral contraceptive hormonal intrauterinedevice willing refrain sexual intercourse begin study three month conclusion study . This serve exclude possibilityof pregnancy sperm could damage study medication A history illness , opinion investigator , might confound result trial pose risk administer trial product subject Known suspect allergy trial product relate product Subject participate trial involve investigational product within last 3 month prior first dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>